GETI.B

198.6

+2%↑

ATT

102.6

+1.38%↑

AMBEA

130.8

+2.19%↑

ARJOB

26.1

+0.08%↑

MSON.B

11.35

+5.09%↑

GETI.B

198.6

+2%↑

ATT

102.6

+1.38%↑

AMBEA

130.8

+2.19%↑

ARJOB

26.1

+0.08%↑

MSON.B

11.35

+5.09%↑

GETI.B

198.6

+2%↑

ATT

102.6

+1.38%↑

AMBEA

130.8

+2.19%↑

ARJOB

26.1

+0.08%↑

MSON.B

11.35

+5.09%↑

GETI.B

198.6

+2%↑

ATT

102.6

+1.38%↑

AMBEA

130.8

+2.19%↑

ARJOB

26.1

+0.08%↑

MSON.B

11.35

+5.09%↑

GETI.B

198.6

+2%↑

ATT

102.6

+1.38%↑

AMBEA

130.8

+2.19%↑

ARJOB

26.1

+0.08%↑

MSON.B

11.35

+5.09%↑

Home・Elenco Azioni・Orexo AB

O
Orexo AB

Chiusa

25.85 1.37

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

25.1

Massimo

26.25

Metriche Chiave
By Trading Economics
Entrata	-68M -116M
Vendite	-115M 3.3M
EPS	20.884
Margine di Profitto	-3,503.03
Dipendenti	72
EBITDA	-262M -272M

Dividendi
By Dow Jones
Utili prossimi	28 apr 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-97M 937M
Apertura precedente	24.48
Chiusura precedente	25.85

Orexo AB Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 mar 2026, 18:43 UTC

Principali Notizie su Eventi

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3 mar 2026, 17:33 UTC

Acquisizioni, Fusioni, Takeovers

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3 mar 2026, 23:45 UTC

Discorsi di Mercato

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3 mar 2026, 23:44 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3 mar 2026, 23:25 UTC

Discorsi di Mercato

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3 mar 2026, 23:25 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

3 mar 2026, 22:38 UTC

Principali Notizie su Eventi

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3 mar 2026, 22:16 UTC

Utili

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3 mar 2026, 22:09 UTC

Utili

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3 mar 2026, 22:06 UTC

Utili

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3 mar 2026, 22:05 UTC

Utili

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3 mar 2026, 22:03 UTC

Utili

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3 mar 2026, 21:50 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Tech, Media & Telecom Roundup: Market Talk

3 mar 2026, 21:50 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Basic Materials Roundup: Market Talk

3 mar 2026, 21:45 UTC

Principali Notizie su Eventi

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3 mar 2026, 21:37 UTC

Utili

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3 mar 2026, 21:26 UTC

Principali Notizie su Eventi

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3 mar 2026, 20:31 UTC

Discorsi di Mercato

Principali Notizie su Eventi

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3 mar 2026, 20:04 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3 mar 2026, 19:17 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold and Silver Drop as Energy Surges -- Market Talk

3 mar 2026, 18:43 UTC

Utili

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3 mar 2026, 18:29 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Global Energy Roundup: Market Talk

3 mar 2026, 18:29 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3 mar 2026, 18:22 UTC

Principali Notizie su Eventi

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3 mar 2026, 18:22 UTC

Principali Notizie su Eventi

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3 mar 2026, 18:17 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3 mar 2026, 18:14 UTC

Utili

How Long Can Anthropic Play Defense? -- WSJ

3 mar 2026, 17:41 UTC

Principali Notizie su Eventi

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3 mar 2026, 17:36 UTC

Principali Notizie su Eventi

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3 mar 2026, 17:28 UTC

Acquisizioni, Fusioni, Takeovers

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Confronto tra pari

Modifica del prezzo

Orexo AB Previsione

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.